ReviewAnnals of medicine and surgery (2012)2025
Stem cell therapy: a paradigm shift in reversing type 1 diabetes mellitus.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder characterized by the destruction of insulin-producing beta cells in the pancreas, necessitating lifelong insulin therapy. Despite advancements in glucose monitoring and insulin delivery, current treatments remain palliative and fail to address the root autoimmune pathology or restore endogenous insulin production. Stem cell therapy has emerged as a promising curative approach due to its dual capacity to regenerate beta cells and modulate immune responses by suppressing autoreactive immune cells and promoting immune tolerance. This review explores the various types of stem cells under investigation - embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, and pancreatic progenitor cells - highlighting their unique advantages and limitations. We delve into mechanisms of action including cell differentiation protocols, immune protection strategies such as encapsulation, and the synergistic use of gene editing to enhance graft survival. Recent preclinical successes and early-phase clinical trials have demonstrated partial insulin independence in up to 40% of participants, with others showing 20-30% reductions in exogenous insulin requirements and measurable increases in C-peptide levels sustained for 6-12 months. However, challenges remain in achieving scalable production, long-term engraftment, and immune tolerance. As research continues to overcome these barriers, stem cell therapy holds transformative potential to shift T1DM treatment from management to functional cure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.